Warrender-Sparkes, MatthewSpelman, TimIzquierdo, GuillermoTrojano, MariaLugaresi, AlessandraGrand'Maison, FrançoisHavrdova, EvaHorakova, DanaBoz, CavitOreja-Guevara, CeliaAlroughani, RaedIuliano, GerardoDuquette, PierreGirard, MarcTerzi, MuratHupperts, RaymondGrammond, PierrePetersen, ThorFernandez-Bolaños, RicardoFiol, MarcelaPucci, EugenioLechner-Scott, JeannetteVerheul, FreekCristiano, EdgardoVan Pesch, VincentPetkovska-Boskova, TatjanaMoore, FraserKister, IlyaBergamaschi, RobertoSaladino, Maria LauraSlee, MarkBarnett, MichaelAmato, Maria PiaShaw, CameronShuey, NeilYoung, CarolynGray, OrlaKappos, LudwigButzkueven, HelmutKalincik, TomasJokubaitis, VilijaMSBase study group2023-01-252023-01-252015-07-21http://hdl.handle.net/10668/10005We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p Following the availability of fingolimod, patients were more likely to discontinue injectable treatments. Those who switched to fingolimod were more likely to do so for convenience. Persistence was improved on fingolimod compared to other medications.enMSBaseMultiple sclerosisdisease-modifying therapyfingolimodmedication persistenceAdministration, OralAdultAgedDemyelinating DiseasesDrug SubstitutionFemaleFingolimod HydrochlorideHumansImmunosuppressive AgentsKaplan-Meier EstimateMaleMedication AdherenceMiddle AgedMultiple Sclerosis, Relapsing-RemittingMultivariate AnalysisProportional Hazards ModelsProspective StudiesRegistriesRisk FactorsTime FactorsTreatment Outcomeresearch article26199347open access10.1177/13524585155940411477-0970http://minerva-access.unimelb.edu.au/bitstreams/63429a6d-6f34-5be1-95b6-5a2b1d4507be/download